A new era of personalised cancer treatments - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

A new era of personalised cancer treatments

As incidence rises, breakthroughs in oncology show the value of research funding

Good news is flowing from the world’s cancer labs. Researchers are reporting encouraging clinical trial results for a diversity of novel treatments, including individualised cancer vaccines, as well as new diagnostic techniques. Various forms of immunotherapy — adapting the patient’s immune system to destroy cancer cells — are proving remarkably successful at extending survival times of some people with refractory tumours.

One reason for the rapid progress is that cancer research has been well funded by industry, governments and charities in comparison with other diseases. Almost 40 per cent of all pharmaceutical R&D investment is directed at clinical oncology — making it the leading field for precision medicine, with diagnostics and drugs tailored to the individual characteristics of patients.

This encouraging lesson about the productivity of research funding has not been lost on scientists working on different diseases, such as dementia and infections, where there is much unmet medical need but relatively less investment. They are right to point to cancer as an example of what can be achieved with more R&D resources.

Moving cancer research breakthroughs rapidly into regular clinical practice will require agile regulators and responsive healthcare providers. They must provide not only appropriate treatment facilities, but diagnostic services to detect tumours as early as possible when chances of a cure are highest.

The new wave of personalised treatments will be expensive when first introduced; immunotherapies often cost more than $100,000 per patient. Pharma companies will inevitably come under pressure to cut what their critics may portray as exorbitant pricing. While drug prices must be subject to some control, the industry’s return on investment should remain high enough to maintain its large, productive cancer research effort. Costs of new medical technologies do come down over time as they are applied more extensively.

Faster diagnosis and better treatments are needed more than ever, as the incidence of cancer continues to rise globally. Disturbingly, cases are growing most rapidly among younger people, for reasons that scientists are only just beginning to understand — and which require urgent investigation. Cancer rates in 25- to 49-year-olds increased by 24 per cent since 1995, according to the charity Cancer Research UK. Although cancer remains largely an affliction of old age, and under-50s still account for no more than 10 per cent of all patients, they represent a much larger proportion of years of healthy life lost to the disease.

Experts believe the rapid increase in obesity in recent decades is one factor driving the growth of tumours such as breast and colorectal cancer among the young. Data presented at the recent American Society of Clinical Oncology conference in Chicago suggests that taking the popular weight loss drugs Ozempic and Wegovy would reduce the risk of developing many common tumours — though, as public health campaigners point out, it would be preferable to tackle obesity by changing people’s diets rather than by medication. Beyond obesity, scientists are looking for carcinogenic signals among the many environmental and lifestyle changes that have taken place over recent decades.

As the disease becomes more prevalent, people are living for longer on average after diagnosis, though progress is currently slow. Human biology means that cancer will always be with us. But the new diagnostic tools and treatments emerging from the world’s labs promise to accelerate the extension of survival time — and make oncology a shining example of the value of biomedical research spending.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

对话Otter.ai的梁松:我们可以从会议和对话中获取有价值的数据

这家会议转录初创公司的联合创始人认为,我们甚至可以用虚拟形象代替自己进行工作互动。

朔尔茨迎来自己的“拜登时刻”

德国总理受到党内压力,要求其效仿美国总统拜登退出竞选。

欧盟极右翼党团在气候和高层任命问题上获得更多支持

欧洲议会中右翼议员正越来越多地与极右翼联手瓦解该集团的绿色议程,并推动更严格的移民限制措施。

毛利人对新西兰后阿德恩时代的民粹主义转向感到愤怒

卢克森的保守党政府推翻了前总理的许多进步政策。

Lex专栏:英伟达令人炫目的增长与每个人都息息相关

这家芯片巨头的盈利对美国股票投资者来说是一件大事,这不仅仅是因为其3.6万亿美元的市值。

欧洲比以往任何时候都更需要企业增长冠军

欧洲正在急切地寻找企业增长冠军,FT-Statista按长期收入增长对欧洲企业进行的首次排名展示了这方面的可能性。
设置字号×
最小
较小
默认
较大
最大
分享×